Encapsulation of the glyphosate herbicide in mesoporous and soil-affine sorbents for its prolonged release

Carrier erythrocytes are emerging as one of the most promising biological drug delivery systems investigated in recent decades. Beside its biocompatibility, biodegradability and ability to circulate throughout the body, it has the ability to perform extended release system of the drug for a long period. The ultimate goal of this study is to introduce a new carrier system for Salbutamol, maintaining suitable blood levels for a long time, as atrial to resolve the problems of nocturnal asthma medication Therefore in this work we study the effect of time, temperature as well as concentration on the loading of salbutamol in human erythrocytes to be used as systemic sustained release delivery system for this drug. After the loading process is performed the carrier erythrocytes were physically and cellulary characterized. Also, the in vitro release of salbutamol from carrier erythrocytes was studied over time interval. From the results it was found that, human erythrocytes have been successfully loaded with salbutamol using endocytosis method either at 25 Co or at 37 Co . The highest loaded amount was 3.5 mg/ml and 6.5 mg/ml respectively. Moreover, the percent of cells recovery is 90.7± 1.64%. Hematological parameters and osmotic fragility behavior of salbutamol loaded erythrocytes were similar that of native erythrocytes. Scanning electron microscopy demonstrated that the salbutamol loaded cells has moderate change in the morphology. Salbutamol releasing from carrier cell was 43% after 36 hours in phosphate buffer saline. The releasing pattern of the drug from loaded erythrocytes showed initial burst release in the first hour followed by a very slow release, obeying zero order kinetics. It concluded that salbutamol is successfully entrapped into erythrocytes with acceptable loading parameters and moderate morphological changes, this suggesting that erythrocytes can be used as prolonged release carrier for salbutamol.

Download Full-text

Faculty Opinions recommendation of Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1060805.512734 ◽

2007 ◽

Author(s):

Robert Macdonald

Keyword(s):

Subarachnoid Hemorrhage ◽

Clinical Outcome ◽

Cerebral Vasospasm ◽

Aneurysmal Subarachnoid Hemorrhage ◽

Prolonged Release ◽

Double Blind

Download Full-text

Formulation and Evaluation of Sustained Release Dosage Forms of Norfloxacin

International Journal of Pharmaceutical Sciences and Nanotechnology ◽

10.37285/ijpsn.2018.11.6.6 ◽

2018 ◽

Vol 11 (6) ◽

pp. 4331-4337

Author(s):

C Suja ◽

Sismy C

Keyword(s):

Sustained Release ◽

Guar Gum ◽

In Vitro Release ◽

Angle Of Repose ◽

Prolonged Release ◽

Weight Variation ◽

Sustained Release Tablets ◽

Release Study ◽

Vitro Release

The goal of this study was to formulate and evaluate norfloxacin sustained release tablets. Norfloxacin sustained release tablets were prepared by wet granulation method using two polymers such as HPMC K 100 M (hydrophilic polymer) and guar gum (natural polymer) and with three polymer ratios (0.5, 1.0 and 1.5). The prepared granules were evaluated to preformulation studies such as angle of repose, bulk density, tapped density, bulkiness, compressibility index and Hauser’s ratio. All the parameters shows that the granules having good flow properties. Then the formulated tablets were taken to evaluation studies such as hardness, weight variation, friability, drug content and thickness. All the parameters were within the acceptable limits. IR spectral analysis showed that there was no interaction between the drug and polymers. The in vitro release study was performed in phosphate buffer pH 7.4 at 293 nm. The in vitro release study showed that if the polymer ratio is increased, then the release of the drug is prolonged. HPMC K 100M shows a prolonged release when compared to guar gum.

Download Full-text

Biodegradation of organophosphorus Pollutants by Soil Bacteria: Biochemical Aspects and Unsolved Problems

Biotekhnologiya ◽

10.21519/0234-2758-2020-36-4-126-135 ◽

2020 ◽

Vol 36 (4) ◽

pp. 126-135

Author(s):

T.V. Shushkova ◽

D.O. Epiktetov ◽

S.V. Tarlachkov ◽

I.T. Ermakova ◽

A.A. Leontievskii

Keyword(s):

Genome Sequencing ◽

Soil Bacteria ◽

Activity Regulation ◽

Bacterial Isolates ◽

Bacterial Strains ◽

Russian Science ◽

Degrading Bacteria ◽

Phosphorus Source ◽

Glyphosate Herbicide ◽

Enzymatic Pathways

The degradation of persistent organophosphorus pollutants have been studied in 6 soil bacterial isolates and in 3 bacterial strains adapted for utilization of glyphosate herbicide (GP) under laboratory conditions. Significant differences in the uptake of organophosphonates were found in taxonomically close strains possessing similar enzymatic pathways of catabolism of these compounds, which indicates the existence of unknown mechanisms of activity regulation of these enzymes. The effect of adaptation for GP utilization as a sole phosphorus source on assimilation rates of several other phosphonates was observed in studied bacteria. The newly found efficient stains provided up to 56% of GP decomposition after application to the soil in the laboratory. The unresolved problems of microbial GP metabolism and the trends for further research on the creation of reliable biologicals capable of decomposing organophosphonates in the environment are discussed. organophosphonates, glyphosate, biodegradation, bioremediation, C-P lyase, phosphonatase, degrading bacteria Investigation of phosphonatase and genome sequencing were supported by Russian Science Foundation Grant no. 18-074-00021.

Download Full-text

Nano-Lipidic Carriers as a Tool for Drug Targeting to the Pilosebaceous Units

Current Pharmaceutical Design ◽

10.2174/1381612826666200515133142 ◽

2020 ◽

Vol 26 (27) ◽

pp. 3251-3268

Author(s):

Shweta Ramkar ◽

Abhishek K. Sah ◽

Nagendra Bhuwane ◽

Ishwari Choudhary ◽

Narayan Hemnani ◽

...

Keyword(s):

Drug Delivery ◽

Hair Follicle ◽

Hair Follicles ◽

Prolonged Release ◽

Pilosebaceous Unit ◽

Tissue Targeting ◽

Bulge Region ◽

Drug Reservoir ◽

Fast Transport ◽

Topical Applications

The pilosebaceous unit is the triad comprising of hair follicle, arrector pilli muscle, and sebaceous gland. Drug delivery to and through the hair follicles has garnered much attention of the researchers and the hair follicles represent an attractive target site via topical applications. They are bordered by capillaries and antigenpresenting cells, connected to the sebaceous glands and the bulge region of the hair follicle anchors the stem cells. The nano lipid carriers have the propensity to penetrate through the skin via transcellular route, intracellular route and follicular route. It has been established that nano lipid carriers have the potential for follicular drug delivery and provide some advantages over conventional pathways, including improved bioavailability, enhanced penetration depth, fast transport into the skin, tissue targeting and form a drug reservoir for prolonged release. This review describes the pilosebaceous unit (PSU) and related diseases and the recent lipid-based nanotechnology approaches for drug delivery to the follicular unit as well as related issues. Different types of nano lipid carriers, including ethosomes, liposomes, nanoparticles, solid lipid nanoparticles (SLNs), and nano lipid carriers (NLCs) have been reported for follicular drug delivery. Targeted drug delivery with nano-lipid carriers has the potential to augment the efficacy of drugs/bioactives to treat diseases of PSU. This review systematically introduces the activities of different formulations and the use of nano lipid carriers in treating PSU related disorders like alopecia, acne, and hirsutism.

Download Full-text

Design of Lamivudine Loaded Nanoparticles for Oral Application by Nano Spray Drying Method: A New Approach to use an Antiretroviral Drug for Lung Cancer Treatment

Combinatorial Chemistry & High Throughput Screening ◽

10.2174/1386207323666200325155020 ◽

2020 ◽

Vol 23 (10) ◽

pp. 1064-1079

Author(s):

Ahmet Alper Öztürk ◽

İrem Namlı ◽

Kadri Güleç ◽

Şennur Görgülü

Keyword(s):

Lung Cancer ◽

Cancer Treatment ◽

Anticancer Activity ◽

Cell Line ◽

Anticancer Drugs ◽

Release Kinetics ◽

Prolonged Release ◽

Lung Cancer Treatment ◽

Anticancer Properties ◽

Ft Ir

Aims: To prepare lamivudine (LAM)-loaded-nanoparticles (NPs) that can be used in lung cancer treatment. To change the antiviral indication of LAM to anticancer. Background: The development of anticancer drugs is a difficult process. One approach to accelerate the availability of drugs is to reclassify drugs approved for other conditions as anticancer. The most common route of administration of anticancer drugs is intravenous injection. Oral administration of anticancer drugs may considerably change current treatment modalities of chemotherapy and improve the life quality of cancer patients. There is also a potentially significant economic advantage. Objective: To characterize the LAM-loaded-NPs and examine the anticancer activity. Methods: LAM-loaded-NPs were prepared using Nano Spray-Dryer. Properties of NPs were elucidated by particle size (PS), polydispersity index (PDI), zeta potential (ZP), SEM, encapsulation efficiency (EE%), dissolution, release kinetics, DSC and FT-IR. Then, the anticancer activity of all NPs was examined. Results: The PS values of the LAM-loaded-NPs were between 373 and 486 nm. All NPs prepared have spherical structure and positive ZP. EE% was in a range of 61-79%. NPs showed prolonged release and the release kinetics fitted to the Weibull model. NPs structures were clarified by DSC and FT-IR analysis. The results showed that the properties of NPs were directly related to the drug:polymer ratio of feed solution. NPs have potential anticancer properties against A549 cell line at low concentrations and non-toxic to CCD 19-Lu cell line. Conclusion: NPs have potential anticancer properties against human lung adenocarcinoma cells and may induce cell death effectively and be a potent modality to treat this type of cancer. These experiments also indicate that our formulations are non-toxic to normal cells. It is clear that this study would bring a new perspective to cancer therapy.

Download Full-text

Moxifloxacin Hydrochloride-Loaded Eudragit® RL 100 and Kollidon® SR Based Nanoparticles: Formulation, In vitro Characterization and Cytotoxicity.

Combinatorial Chemistry & High Throughput Screening ◽

10.2174/1386207323666200428091945 ◽

2020 ◽

Vol 23 ◽

Cited By ~ 2

Author(s):

Gülsel Yurtdaş Kırımlıoğlu ◽

Sinan Özer ◽

Gülay Büyükköroğlu ◽

Yasemin Yazan

Keyword(s):

Particle Size ◽

Zeta Potential ◽

Spray Drying ◽

Prolonged Release ◽

Ocular Delivery ◽

Corneal Permeability ◽

Release Pattern ◽

In Vitro Characterization ◽

Ocular Bioavailability

Background: Considering the low ocular bioavailability of conventional formulations used for ocular bacterial infection treatment, there’s a need for designing efficient novel drug delivery systems that may enhance of precorneal retention time and corneal permeability. Aim and Objective: The current research focuses on developing nanosized and non-toxic Eudragit® RL 100 and Kollidon® SR nanoparticles loaded with moxifloxacin hydrochloride (MOX) for its prolonged release to be promising for effective ocular delivery. Methods: In this study, MOX was incorporation was carried out by spray drying method aiming ocular delivery. In vitro characteristics were evaluated in detail with different methods. Results: MOX was successfully incorporated into Eudragit® RL 100 and Kollidon® SR polymeric nanoparticles by spray-drying process. Particle size, zeta potential, entrapment efficiency, particle morphology, thermal, FTIR, XRD and NMR analyses and MOX quantification using HPLC method were carried out to evaluate the nanoparticles prepared. MOX loaded nanoparticles demonstrated nanosized and spherical shape while in vitro release studies demonstrated modified release pattern which followed Korsmeyer-Peppas kinetic model. Following successful incorporation of MOX into the nanoparticles, the formulation (MOX: Eudragit® RL 100, 1:5) (ERL-MOX 2) was selected for further studies by the reason of its better characteristics like cationic zeta potential, smaller particle size, narrow size distribution and more uniform prolonged release pattern. Moreover, ERL-MOX 2 formulation remained stable for 3 months and demonstrated higher cell viability values for MOX. Conclusion: In vitro characterization analyses showed that non-toxic, nano-sized and cationic ERLMOX 2 formulation has the potential of enhancing ocular bioavailability.

Download Full-text